John M. Evans - Oct 1, 2025 Form 4 Insider Report for Beam Therapeutics Inc. (BEAM)

Role
CEO, Director
Signature
By: /s/ Christine Bellon, Attorney-in-fact
Stock symbol
BEAM
Transactions as of
Oct 1, 2025
Transactions value $
-$1,194,823
Form type
4
Date filed
10/3/2025, 04:05 PM
Previous filing
Apr 3, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Evans John M. CEO, Director C/O BEAM THERAPEUTICS INC.,, 238 MAIN STREET, CAMBRIDGE By: /s/ Christine Bellon, Attorney-in-fact 2025-10-03 0001786304

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BEAM Common Stock Options Exercise $16.8K +25K +2.53% $0.67 1.01M Oct 1, 2025 Direct F1, F2
transaction BEAM Common Stock Sale -$613K -25K -2.47% $24.51 987K Oct 1, 2025 Direct F1, F3
transaction BEAM Common Stock Options Exercise $16.8K +25K +2.53% $0.67 1.01M Oct 2, 2025 Direct F1
transaction BEAM Common Stock Sale -$616K -25K -2.47% $24.63 987K Oct 2, 2025 Direct F1, F4
holding BEAM Common Stock 103K Oct 1, 2025 By John M. Evans, III 2018 Irrevocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BEAM Stock Option (Right to Buy) Options Exercise $0 -25K -36.06% $0.00 44.3K Oct 1, 2025 Common Stock 25K $0.67 Direct F1, F5
transaction BEAM Stock Option (Right to Buy) Options Exercise $0 -25K -56.39% $0.00 19.3K Oct 2, 2025 Common Stock 25K $0.67 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.
F2 Includes 418 shares acquired by the Reporting Person under the Beam Therapeutics Inc. ("BEAM") Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2025.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $24.14 to $24.92, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $24.22 to $25.05, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a closing hurdle following BEAM's initial public offering (which closing price hurdle was achieved) (the "Price Condition"). The portion of the award subject to the Price Condition vested in three equal installments on December 21, June 30, 2022, and December 31, 2022.